Literature DB >> 17012697

Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia.

Rodrigo D Paz1, Nancy C Andreasen, Sami Z Daoud, Robert Conley, Rosalinda Roberts, Juan Bustillo, Nora I Perrone-Bizzozero.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the functional state of glutamatergic neurons in the cerebellar cortex of patients with schizophrenia.
METHOD: The authors measured messenger ribonucleic acid (mRNA) levels of three activity-dependent genes expressed by glutamatergic neurons in the cerebellar cortex (GAP-43, BDNF, and GABA OLE_LINK2>(A)-delta subunit) in the tissues of 14 patients with schizophrenia and 14 matched nonpsychiatric comparison subjects. Since its level of expression does not change in response to neuronal activity, gamma-aminobutyric acid(A)-alpha6 subunit mRNA was used as a control.
RESULTS: The levels of GAP-43 and BDNF mRNAs were significantly elevated in patients with schizophrenia, and a similar finding was observed for GABA(A)-delta mRNA. In contrast, the levels of the GABA(A)-alpha6 subunit mRNA, which is expressed in cerebellar granule cells in an activity-independent manner, did not differ from comparison subjects.
CONCLUSIONS: These results suggest that glutamatergic neurons may be hyperactive in the cerebellar cortices of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012697     DOI: 10.1176/ajp.2006.163.10.1829

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  16 in total

1.  Coordinated expression of HuD and GAP-43 in hippocampal dentate granule cells during developmental and adult plasticity.

Authors:  Federico Bolognani; Daniel C Tanner; Sayuri Nixon; Hirotaka J Okano; Hideyuki Okano; Nora I Perrone-Bizzozero
Journal:  Neurochem Res       Date:  2007-06-19       Impact factor: 3.996

Review 2.  The role of the cerebellum in schizophrenia.

Authors:  Nancy C Andreasen; Ronald Pierson
Journal:  Biol Psychiatry       Date:  2008-04-08       Impact factor: 13.382

3.  Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder.

Authors:  Benchawanna Soontornniyomkij; Ian P Everall; Gursharan Chana; Ming T Tsuang; Cristian L Achim; Virawudh Soontornniyomkij
Journal:  J Affect Disord       Date:  2011-05-25       Impact factor: 4.839

4.  Opposite effects of acute ethanol exposure on GAP-43 and BDNF expression in the hippocampus versus the cerebellum of juvenile rats.

Authors:  V V Kulkarny; N E Wiest; C P Marquez; S C Nixon; C F Valenzuela; N I Perrone-Bizzozero
Journal:  Alcohol       Date:  2011-03-02       Impact factor: 2.405

5.  Cerebellar-dependent eyeblink conditioning deficits in schizophrenia spectrum disorders.

Authors:  Jennifer K Forsyth; Amanda R Bolbecker; Crystal S Mehta; Mallory J Klaunig; Joseph E Steinmetz; Brian F O'Donnell; William P Hetrick
Journal:  Schizophr Bull       Date:  2010-12-09       Impact factor: 9.306

6.  Serum Level of Growth-Associated Protein 43 Is Associated with First-Episode Schizophrenia Patients without Antipsychotic Drugs Treatment.

Authors:  Libin Xiao; Xiaowei Tang; Xiuxiu Hu; Xiaotang Feng; Ronglan Gong; Fujun Wang; Xiangrong Zhang
Journal:  Comput Intell Neurosci       Date:  2022-05-16

7.  A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2009-07-03       Impact factor: 5.858

8.  Glutamate Neurotransmission in Psychotic Disorders and Substance Abuse.

Authors:  Berit Kerner
Journal:  Open Psychiatr J       Date:  2009-01-01

Review 9.  Modulating neural plasticity with non-invasive brain stimulation in schizophrenia.

Authors:  Alkomiet Hasan; Thomas Wobrock; Tarek Rajji; Berend Malchow; Zafiris J Daskalakis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-09-24       Impact factor: 5.270

Review 10.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.